# US 2004/0203095 A1 · Method for producing recombinant trypsin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0203095 A1
- Document ID: US20040203095A1
- Status: Published application
- Kind: A1
- Application number: 10/470,508
- Filed: 2004-04-12
- Published: 2004-10-14
- Earliest claimed: 2001-02-01
- Assignees: Roche Diagnostics Operations, Inc.
- Inventors: Rainer Muller; Stephan Glaser; Frank Geipel; Johann-Peter Thalhofer; Bernhard Rexer; Claus Schneider; Michael Ratka; Stephanie Ronning; Hellmut Eckstein; Claudia Giessel
- Web page: https://patentgrep.com/patent/US20040203095A1

## CPC

- C12N 9/6427: {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention concerns a method for producing recombinant trypsin from porcine pancreas in Pichia pastoris which is soluble and secreted into the culture medium, whereby expression at pH 3.0-4.0 substantially prevents activation of trypsinogen to β-trypsin and autolysis of β-trypsin by α-trypsin into ε-trypsin and from there into inactive peptides.

## Claims

### Claim 1

A method for the recombinant production of trypsin comprising the steps:
a) transforming a host cell with a recombinant nucleic acid which codes for a trypsinogen with an enterokinase recognition site in the propeptide sequence in a form that can be secreted by the host cell,
b) culturing the host cell under conditions which enable an expression of the recombinant nucleic acid and a secretion of the expression product into the culture medium, the conditions being selected such that an autocatalytic cleavage of the propeptide sequence is substantially prevented,
c) isolating the expression product from the culture medium,
d) cleaving the propeptide sequence to form active trypsin and
e) optionally separating non-cleaved trypsinogen molecules from active trypsin.

### Claim 2 (depends on 1)

A method as claimed in claim 1, wherein a yeast cell is used as the host cell.

### Claim 3 (depends on 1)

A method as claimed in claim 1, wherein Pichia pastoris or Hansenula polymorpha is used as the host cell.

### Claim 4 (depends on 1)

A method as claimed in claim 1, wherein a recombinant nucleic acid is used which codes for a trypsinogen fused to a signal peptide that mediates secretion.

### Claim 5 (depends on 1)

A method as claimed in claim 1, wherein a recombinant nucleic acid with an optimized codon usage for the host cell is used.

### Claim 6 (depends on 1)

A method as claimed in claim 1, wherein a recombinant nucleic acid is used which codes for a trypsinogen having a shortened propeptide sequence.

### Claim 7 (depends on 1)

A method as claimed in claim 1, wherein a recombinant nucleic acid is used which codes for a porcine trypsinogen.

### Claim 8 (depends on 1)

A method as claimed in claim 1, wherein a recombinant nucleic acid is used having the nucleotide sequence shown in SEQ ID NO. 22.

### Claim 9 (depends on 1)

A method as claimed in claim 1, wherein the recombinant nucleic acid is expressed under acidic conditions in particular at pH 3-4.

### Claim 10 (depends on 9)

A method as claimed in claim 9, wherein the host cell is cultured before expression of the recombinant nucleic acid under conditions that are essentially optimal for the growth of the host cell.

### Claim 11 (depends on 10)

A method as claimed in claim 10, wherein the host cell is cultured before expression of the recombinant nucleic acid at pH 5-7 up to a predetermined optical density and then the expression of the recombinant nucleic acid is induced.

### Claim 12 (depends on 1)

A method as claimed in claim 1, wherein the propeptide sequence is cleaved by addition of recombinant trypsin or/and by autocatalytic cleavage.

### Claim 13 (depends on 1)

A method as claimed in claim 1, wherein the culture medium containing the host cells is admixed with a buffer containing calcium ions and subsequently the steps (c), (d) and optionally (e) are carried out.

### Claim 14

A nucleic acid comprising a recombinant nucleic acid that codes for a trypsinogen having an enterokinase recognition site in the propeptide sequence, wherein the propeptide sequence is shortened compared to the natural propeptide sequence.

### Claim 15 (depends on 14)

A nucleic acid as claimed in claim 14, wherein the propeptide sequence consists of an enterokinase recognition site having the amino acid sequence Asp-Asp-Asp-Asp-Lys and optionally up to 5 additional amino acids located N-terminal thereof.

### Claim 16 (depends on 14)

A nucleic acid as claimed in claim 14, wherein the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO. 22.

### Claim 17 (depends on 14)

A nucleic acid as claimed in claim 14, wherein the nucleic acid is in operative linkage with a regulatable expression control sequence.

### Claim 18 (depends on 14, 15, 16, 17)

A recombinant vector comprising at least one copy of a recombinant nucleic acid as claimed in one of the claims 14 to 17.

### Claim 19 (depends on 14, 15, 16, 17, 18)

A recombinant host cell, wherein the cell is transformed with a nucleic acid as claimed in one of the claims 14 to 17 or with a vector as claimed in claim 18.

### Claim 20

A recombinant trypsinogen comprising a trypsin sequence and a propeptide sequence which is shortened compared to the natural propeptide sequence and contains an enterokinase recognition site.

### Claim 21 (depends on 20)

Trypsinogen as claimed in claim 20, wherein the propeptide sequence consists of an enterokinase recognition site having the amino acid sequence Asp-Asp-Asp-Asp-Lys and optionally up to 5 additional amino acids located N-terminal thereof.

### Claim 22 (depends on 20)

Trypsinogen as claimed in claim 20, wherein the trypsinogen has the amino acid sequence shown in SEQ ID NO. 23.
